Technical Analysis for GLTO - Galecto, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.47 | -1.73% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -1.73% | |
| Stochastic Reached Oversold | Weakness | -1.73% | |
| Gapped Down | Weakness | -1.73% | |
| Oversold Stochastic | Weakness | -1.73% | |
| Outside Day | Range Expansion | -7.32% | |
| New 52 Week Closing Low | Bearish | -4.88% | |
| NR7 | Range Contraction | -4.88% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Rose Above 10 DMA | about 8 hours ago |
| Up 5% | about 8 hours ago |
| 2x Volume Pace | about 9 hours ago |
| 1.5x Volume Pace | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 07/29/2024
Galecto, Inc. Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Breakthrough Therapy Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Progressive Fibrosis mTOR Fibrotic Disease Lectins Lung Diseases Treatment Of Fibrosis Copenhagen Galectin Myelofibrosis Galectin 3 Galecto Biotech
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.7 |
| 52 Week Low | 0.4637 |
| Average Volume | 148,431 |
| 200-Day Moving Average | 0.65 |
| 50-Day Moving Average | 0.61 |
| 20-Day Moving Average | 0.52 |
| 10-Day Moving Average | 0.49 |
| Average True Range | 0.04 |
| RSI (14) | 32.43 |
| ADX | 39.1 |
| +DI | 10.80 |
| -DI | 20.44 |
| Chandelier Exit (Long, 3 ATRs) | 0.51 |
| Chandelier Exit (Short, 3 ATRs) | 0.58 |
| Upper Bollinger Bands | 0.59 |
| Lower Bollinger Band | 0.45 |
| Percent B (%b) | 0.11 |
| BandWidth | 25.73 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.52 | ||||
| Resistance 3 (R3) | 0.53 | 0.51 | 0.51 | ||
| Resistance 2 (R2) | 0.51 | 0.50 | 0.51 | 0.51 | |
| Resistance 1 (R1) | 0.49 | 0.49 | 0.48 | 0.48 | 0.50 |
| Pivot Point | 0.48 | 0.48 | 0.47 | 0.47 | 0.48 |
| Support 1 (S1) | 0.45 | 0.46 | 0.45 | 0.45 | 0.43 |
| Support 2 (S2) | 0.44 | 0.45 | 0.44 | 0.42 | |
| Support 3 (S3) | 0.42 | 0.44 | 0.42 | ||
| Support 4 (S4) | 0.41 |
